Blog
Atezolizumab Biosimilar : Enhancing Access to PD-L1 Immunotherapy
Atezolizumab (Tecentriq) is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), a key immune checkpoint used by cancer cells to evade immune detection. By inhibiting PD-L1
…
25th Nov 2024